Connor, Clark & Lunn Investment Management Ltd. Surface Oncology, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$1.05 - $2.1 $102,965 - $205,930	98,062 New	98,062 $102,000
Q1 2022 May 12, 2022	SELL	$2.65 - $5.08 $31,709 - $60,787	-11,966 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$4.73 - $7.9 $148,209 - $247,538	-31,334 Reduced 72.36%	11,966 $57,000
Q3 2021 Nov 12, 2021	BUY	$5.16 - $7.98 $223,428 - $345,534	43,300 New	43,300 $328,000

Others Institutions Holding SURF

# of Institutions

Shares Held

315K

Call Options Held

Put Options Held

Act Capital Management, LLC Wayne, PA

171K
Shares

$0
0.24% of portfolio
Kingsbury Capital Investment Advisors LLC Evanston, IL

144K
Shares

$0
0.23% of portfolio

View Full List

About Surface Oncology, Inc.

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

More about SURF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account